EA201890478A1 - Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы - Google Patents

Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы

Info

Publication number
EA201890478A1
EA201890478A1 EA201890478A EA201890478A EA201890478A1 EA 201890478 A1 EA201890478 A1 EA 201890478A1 EA 201890478 A EA201890478 A EA 201890478A EA 201890478 A EA201890478 A EA 201890478A EA 201890478 A1 EA201890478 A1 EA 201890478A1
Authority
EA
Eurasian Patent Office
Prior art keywords
contact system
activation
assess
blood collection
protease inhibitors
Prior art date
Application number
EA201890478A
Other languages
English (en)
Inventor
Дэниел Дж. Секстон
Райан Фосетт
Original Assignee
Дайэкс Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайэкс Корп. filed Critical Дайэкс Корп.
Publication of EA201890478A1 publication Critical patent/EA201890478A1/ru

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B01L3/5082—Test tubes per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150015—Source of blood
    • A61B5/15003—Source of blood for venous or arterial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
    • A61B5/154—Devices using pre-evacuated means
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/16—Reagents, handling or storing thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0832—Geometry, shape and general structure cylindrical, tube shaped
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В настоящем документе предложена вакуумная пробирка для забора крови, содержащая коктейль ингибиторов протеазы в жидкой форме, и ее применение для оценки признаков, связанных с контактной системой у индивида, включая эндогенный уровень активации контактной системы, эндогенный уровень лекарственного средства, которое нацелено на компонент контактной системы во время лечения, и/или иммуногенность такого лекарственного средства.
EA201890478A 2015-08-13 2016-08-12 Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы EA201890478A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562204644P 2015-08-13 2015-08-13
US201562214308P 2015-09-04 2015-09-04
PCT/US2016/046681 WO2017027771A1 (en) 2015-08-13 2016-08-12 Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation

Publications (1)

Publication Number Publication Date
EA201890478A1 true EA201890478A1 (ru) 2018-07-31

Family

ID=56802683

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890478A EA201890478A1 (ru) 2015-08-13 2016-08-12 Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы

Country Status (15)

Country Link
US (3) US10870115B2 (ru)
EP (2) EP3334343B1 (ru)
JP (3) JP6907188B2 (ru)
KR (1) KR20180100107A (ru)
CN (2) CN116196995A (ru)
AU (2) AU2016306653B2 (ru)
BR (1) BR112018002742B1 (ru)
CA (1) CA2995457A1 (ru)
CO (1) CO2018002531A2 (ru)
EA (1) EA201890478A1 (ru)
ES (1) ES2938089T3 (ru)
HK (1) HK1255461A1 (ru)
IL (3) IL295914B1 (ru)
MX (2) MX2018001786A (ru)
WO (1) WO2017027771A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180100107A (ko) 2015-08-13 2018-09-07 다이액스 코포레이션 접촉 시스템 활성화의 평가를 위한 프로테아제 저해제를 함유하는 진공 채혈관
CN109716137B (zh) 2016-09-16 2023-07-21 武田药品工业株式会社 用于与接触活化系统相关的疾病的代谢产物生物标记
WO2024003617A2 (en) 2022-06-30 2024-01-04 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
DE69533472T2 (de) 1994-01-11 2006-01-12 Dyax Corp., Cambridge Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon
JP3622286B2 (ja) * 1995-09-01 2005-02-23 日東紡績株式会社 α２ −プラスミンインヒビタ−の測定方法及び測定試 薬
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
WO2003097237A2 (en) * 2002-05-13 2003-11-27 Becton, Dickinson, And Company Protease inhibitor sample collection system
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
AU2005218555B2 (en) * 2004-03-01 2008-01-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
DE602005009252D1 (de) 2004-12-08 2008-10-02 Bristol Myers Squibb Co Heterocyclische verbindungen als inhibitoren von faktor viia
WO2006089005A2 (en) 2005-02-17 2006-08-24 Bristol-Myers Squibb Company Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP2030013B1 (en) * 2006-06-06 2009-12-16 Roche Diagnostics GmbH Ready-to-use whole blood collection vessel
US20080286818A1 (en) * 2007-05-18 2008-11-20 Datwyler Saul A Blood sample handling methods for improved assays for myeloperoxidase
BRPI0812398A2 (pt) * 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
WO2009022001A1 (en) * 2007-08-16 2009-02-19 Novartis Ag Improvement of drug tolerance in immunogenicity testing
US8283160B2 (en) * 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
US7985188B2 (en) 2009-05-13 2011-07-26 Cv Holdings Llc Vessel, coating, inspection and processing apparatus
US9642817B2 (en) * 2009-08-27 2017-05-09 Technion Research & Development Foundation Limited Liposomal compositions and uses of same
WO2011033046A1 (en) * 2009-09-18 2011-03-24 Probiodrug Ag Novel assay for the detection of amyloid beta peptides
CN102740888B (zh) * 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
BR112013009376A2 (pt) * 2010-10-18 2016-07-26 Nestec Sa métodos para determinar isótipos de anticorpos antifármacos
US9459187B2 (en) * 2011-03-04 2016-10-04 Becton, Dickinson And Company Blood collection device containing lysophospholipase inhibitor
GB201114017D0 (en) * 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
CA2862544A1 (en) * 2012-02-02 2013-08-08 Randal Alan Hoke Sample collection devices with blood stabilizing agents
SG11201505978PA (en) * 2013-02-01 2015-08-28 Becton Dickinson Co Blood collection devices containing contact pathway inhibition additives
JP2017501968A (ja) 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
KR102432826B1 (ko) * 2013-10-21 2022-08-16 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR20180100107A (ko) 2015-08-13 2018-09-07 다이액스 코포레이션 접촉 시스템 활성화의 평가를 위한 프로테아제 저해제를 함유하는 진공 채혈관

Also Published As

Publication number Publication date
IL257209A (en) 2018-04-30
US10870115B2 (en) 2020-12-22
CO2018002531A2 (es) 2018-06-12
US20190022641A1 (en) 2019-01-24
IL311909A (en) 2024-06-01
AU2016306653A1 (en) 2018-02-22
CN108135547B (zh) 2023-01-10
BR112018002742B1 (pt) 2023-05-16
AU2021215261A1 (en) 2021-09-02
JP2021164678A (ja) 2021-10-14
JP2018532100A (ja) 2018-11-01
EP3334343B1 (en) 2022-10-19
IL295914A (en) 2022-10-01
CA2995457A1 (en) 2017-02-16
IL257209B (en) 2022-09-01
AU2021215261B2 (en) 2023-10-12
US11458477B2 (en) 2022-10-04
JP7242765B2 (ja) 2023-03-20
MX2018001786A (es) 2018-06-06
JP2023078232A (ja) 2023-06-06
ES2938089T3 (es) 2023-04-04
BR112018002742A2 (ru) 2018-10-02
KR20180100107A (ko) 2018-09-07
JP6907188B2 (ja) 2021-07-21
CN116196995A (zh) 2023-06-02
NZ739623A (en) 2023-09-29
US11826758B2 (en) 2023-11-28
EP3909509A1 (en) 2021-11-17
AU2016306653B2 (en) 2021-05-13
MX2022014713A (es) 2022-12-16
IL295914B1 (en) 2024-05-01
HK1255461A1 (zh) 2019-08-16
CN108135547A (zh) 2018-06-08
US20230182139A1 (en) 2023-06-15
WO2017027771A1 (en) 2017-02-16
EP3334343A1 (en) 2018-06-20
US20210322972A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
BR112015027477A8 (pt) bolus, seus usos, e kit
EA201691647A1 (ru) Способы кратковременного и долгосрочного лечения зависимости от лекарственных средств
EA201890478A1 (ru) Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
EA201791183A1 (ru) Шприц и связанная игла
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
EA201700254A1 (ru) Комбинация
EA201691596A1 (ru) Составы гепарина для наружного применения
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX2016015799A (es) Aparato, sistemas y metodos para detectar un analito tal como etanol.
MX2020007221A (es) Herramientas y sistemas de suministro de dispositivos.
EA201792130A1 (ru) Композиции, содержащие adamts13, для применения в способах реканализации окклюзированных кровеносных сосудов при инфаркте
WO2016107874A3 (en) Prenylcysteine oxidase 1 inhibitors for the prevention and/or treatment of oxidative stress-related degenerative diseases and prenylcysteine oxidase 1 as diagnostic marker
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
EA201691393A1 (ru) Методы анализа клиренса субстрата для лизосомальных ферментов